Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | ALK R1275Q AXL pos |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| ALK R1275Q AXL pos | neuroblastoma | sensitive | Bemcentinib + Ceritinib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Bemcentinib (BGB-324) to treatment with Zykadia (ceritinib) increased Zykadia (ceritinib)-induced apoptosis in an AXL-expressing neuroblastoma cell line harboring ALK R1275Q in culture (PMID: 25450694). | 25450694 | |
| ALK R1275Q AXL pos | neuroblastoma | sensitive | Bemcentinib + Crizotinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the addition of Bemcentinib (BGB-324) to Xalkori (crizotinib) treatment increased Xalkori (crizotinib)-induced apoptosis in an AXL-expressing neuroblastoma cell line harboring ALK R1275Q in culture, and improved efficacy in xenograft models (PMID: 25450694). | 25450694 |